Peace, Teva dropped ATL1102 when Antisense was still a struggling unproven product. After 20 years only one Antisense product had reached the market and in 1998 that did not last long. In addition the cost at that time to do a new toxicology study within America was a lot more than the $300K we are spending in China. Also sometimes CEO's have their own agenda and or lack of vision. Since then the acceptance and desire for Antisense has shifted radically. I would not be surprised if we see Teva back in before the end of 1st Qtr 2014, only this time it will not be for a paltry $5M
ANP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
